×

ImmunoGen, Inc. Announces Exercise of Over-Allotment Option

WALTHAM, Mass., May 10, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public offering price of $8.00 per share.

The exercise of the over-allotment option brings the total shares of common stock to be sold by ImmunoGen in the offering to 10,350,000 shares. Net proceeds, after underwriting discounts and commissions and estimated expenses, will be approximately $77.6 million. The offering is expected to close on or about May 12, 2010, subject to satisfaction of customary closing conditions.

J.P. Morgan Securities Inc. is acting as the sole book-runner for the offering and Oppenheimer & Co. Inc., RBC Capital Markets Corporation, Cantor Fitzgerald & Co. and Morgan Joseph & Co. Inc. are acting as co-managers.

The securities described above are being offered by ImmunoGen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering. The offering may be made only by means of a prospectus, copies of which may be obtained, when available, from J.P. Morgan Securities Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 1-866-803-9204.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's potent cell-killing agents specifically to tumor targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech/Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the public offering. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and other reports filed with the Securities and Exchange Commission.

SOURCE: ImmunoGen CONTACT: ImmunoGen, Inc. Carol Hausner, 781-895-0600 Executive Director, Investor Relations and Corporate Communications info@immunogen.com Copyright Business Wire 2010 -0- KEYWORD: United States

North America

Massachusetts INDUSTRY KEYWORD: Health

Biotechnology

Pharmaceutical

Professional Services

Finance